Why this is a diagnosis decision, not a product preference

Most patients researching these two treatments encounter them side by side — two injections, similar price points, both aimed at knee pain — and assume the decision is a matter of preference or evidence. It is not. ChondroFiller® and Arthrosamid® address fundamentally different types of cartilage problem, and in most cases the diagnosis determines which is appropriate before personal preference enters the picture at all.

Think of the distinction this way. ChondroFiller® is a collagen scaffold injected into a discrete, localised cartilage defect — a pothole in an otherwise reasonable road surface. It works through acellular matrix-induced chondrogenesis: the scaffold recruits the patient's own progenitor cells to migrate in and rebuild cartilage matrix within that specific lesion over six to twelve months. Arthrosamid®, by contrast, is a non-biodegradable polyacrylamide hydrogel that coats the synovial membrane across the whole joint. It does not repair or regenerate cartilage; it cushions a joint whose surface has worn down broadly — a road where the entire surface needs resurfacing rather than a single pothole filling.

A patient with a focal post-traumatic defect and one with grade III diffuse osteoarthritis are not choosing between two solutions to the same problem. They have different problems. Framing this comparison as a head-to-head preference misrepresents the clinical decision entirely. The useful starting point — the one this article is structured around — is understanding which pattern of damage a patient actually has, because that is what makes the choice straightforward.

What ChondroFiller does and when it fits

ChondroFiller® is manufactured by Meidrix Biomedicals GmbH in Germany and is CE-marked as a Class III medical device. In practice, it is delivered as an ultrasound-guided outpatient injection — no theatre admission, no general anaesthetic, no incisions. The liquid scaffold is placed directly into the mapped defect under real-time imaging, where it sets into a gel within minutes and occupies the lesion space.

The repair that follows is gradual. Over six to twelve months, the patient's own progenitor cells migrate into the collagen lattice and lay down new cartilage matrix within the defect — a process measurable on follow-up MRI, where published series report MOCART regeneration scores of 70–87. Knee function, measured by the IKDC score, has shown improvements of approximately 30 points in selected patients. These are not immediate results; the scaffold does its work over several months, and patients should not expect rapid symptom relief in the way they might from a corticosteroid injection.

Patient selection is where the clinical decision is made. ChondroFiller® suits focal, contained cartilage lesions — post-traumatic defects, osteochondritis dissecans, sports-related chondral injuries — in a joint whose surrounding cartilage is reasonably intact. When osteoarthritis has spread through the joint generally, outcomes are considerably poorer: in a published hip cohort, patients with Tönnis grade 2–3 OA at baseline fared substantially worse than those with isolated focal lesions, while 17 of 21 patients with discrete defects achieved good or excellent results at three to five years. The surrounding joint needs to be in reasonable condition for the scaffold to work as intended. Age, however, is a less decisive factor; no published upper age limit applies to the treatment.

One meaningful differentiator is joint scope. ChondroFiller® has been used across the knee, hip, shoulder, ankle, elbow, foot, hand and wrist — making it the only option in this comparison when cartilage damage involves a joint other than the knee.

What Arthrosamid does and when it fits

Arthrosamid® takes a different route to pain relief entirely. Made by Contura A/S, it is a 2.5% cross-linked polyacrylamide hydrogel — 97.5% water — administered as a single 6 ml intra-articular injection under ultrasound guidance in an outpatient setting. Once injected, it adheres to the synovial membrane and remains there permanently; it does not break down or require repeat dosing. The mechanism is cushioning and pain modulation rather than tissue restoration: it bulks up the synovial lining, providing a viscoelastic buffer within a joint whose cartilage has worn diffusely. An NHS-funded study at RJAH is currently under way to characterise precisely how the hydrogel modulates pain signalling — the full mechanism remains an area of active investigation.

The treatment is licensed for the knee joint only. It cannot be used in the hip, shoulder, ankle, or any other joint.

The published evidence is most convincing on durability. A five-year single-arm extension study (49 participants; 27 completing five years) demonstrated sustained, statistically significant improvements in WOMAC pain (−14.6), stiffness (−19.6), and physical function (−12.5) from a single injection, with no serious device-related adverse events reported. A systematic review pooling 463 patients confirmed significant patient-reported outcome improvements at 52 weeks, 13 months, and two years; no long-lasting adverse events were identified across that pooled population. In a 150-patient comparative study, Arthrosamid® maintained slight VAS improvement at 12 months while hyaluronic acid and corticosteroid had returned to baseline — though the between-group difference at 12 months was not statistically significant.

Patient selection matters here too. In the largest prospective cohort (314 knees, 24 months), the patients most likely to reach a clinically meaningful improvement were older, non-diabetic, with lower Kellgren–Lawrence grades and bilateral knee involvement — pointing towards early-to-moderate osteoarthritis as the sweet spot rather than severe end-stage disease. Forty-nine patients in that cohort went on to total knee replacement within two years, most from the higher-grade OA group.

The same cohort reported complications in 155 of 314 knees (49%). That figure warrants careful reading: the study does not disaggregate by severity, and pooled data across the wider evidence base have not identified long-lasting adverse events. The number reflects all reported events, including minor or transient ones, rather than serious harms alone — but a patient considering this treatment should discuss the full picture with a consultant rather than relying on either the headline figure or a reassuring summary alone.

Comparing outcomes and what the evidence can and cannot tell you

No direct trial has ever compared ChondroFiller® with Arthrosamid® — and none is expected, because they are designed for different stages of joint disease. Comparing their evidence bases is useful not to rank them but to understand what each body of research is actually measuring.

ChondroFiller®'s published data comes from smaller cohorts. The pivotal knee study enrolled 13 patients in the active arm; the hip series followed 21 patients to three-to-five years. Over 19,000 procedures have been performed globally, which provides meaningful real-world breadth, and a published complaint rate of approximately 0.06% across that experience speaks to a clean safety profile. What the literature currently lacks is a large knee RCT with follow-up beyond 12 months — the existing controlled data shows sustained functional gains within that window, but longer-term cartilage durability in the knee specifically remains an evidence gap.

Arthrosamid®'s evidence base is broader in scale and longer in duration. A systematic review pooling 463 patients confirmed meaningful patient-reported improvements at two years; a five-year extension study demonstrated that those gains persist from a single injection, with no serious device-related adverse events. In comparative data, it outlasts both hyaluronic acid and corticosteroid, though the absolute difference versus hyaluronic acid at 12 months was not statistically significant — the advantage lies in durability rather than magnitude. One mechanistic question remains open: precisely how the hydrogel modulates pain — whether through synovial cushioning, viscoelastic load distribution, or neurogenic pathways — is still under active clinical investigation.

The honest summary is that both treatments carry genuinely supportive evidence, but they have been tested in different patient populations, at different scales, and over different follow-up periods. A consultation that maps the individual patient's imaging, OA grade, and functional goals to the appropriate evidence set is a more reliable guide than any side-by-side comparison of the two.

Cost, access and what to expect at your appointment

Practical considerations often shape a patient's decision as much as clinical evidence does — and for both treatments, the logistics follow a similar pattern.

Neither ChondroFiller® nor Arthrosamid® is covered by the NHS or by private medical insurance. Both are regulated as CE-marked medical devices rather than pharmaceutical drugs, which means neither sits on an NHS formulary or a PMI reimbursement list. Both are entirely self-funded. Guide costs are broadly comparable — starting at around £3,000 — though the precise figure varies by joint and case complexity; patients should confirm current pricing directly with the clinic at the point of enquiry.

The injection pathway is the same category of procedure for both: an ultrasound-guided outpatient injection carried out at a clinic appointment, with no theatre admission, no general anaesthetic, and no surgical incision. ChondroFiller® is placed into the mapped focal defect under real-time ultrasound guidance; Arthrosamid® is delivered into the knee joint space with the same image-guided precision. Patients typically leave the same day.

Recovery diverges after the procedure. With Arthrosamid®, the hydrogel integrates with the synovial membrane and any pain-modulating effect tends to develop over subsequent weeks. ChondroFiller® requires a period of restricted weight-bearing while the collagen scaffold stabilises within the defect; the regenerative process then unfolds over six to twelve months and can be assessed on follow-up MRI where clinically indicated.

Consultant-led assessments are available at the Regeneration Hub in Sleaford (NG34) and at the diagnostics and consultation centre in Grantham (NG31) — no GP letter is needed, and appointments can be booked directly at mskdoctors.com.

Getting an accurate diagnosis before choosing

The clinical decision tree here is more tractable than it might appear. Imaging — typically MRI — clarifies three things that directly drive the treatment choice: whether the cartilage damage is focal or diffuse, how much of the joint surface is involved, and the degree of underlying osteoarthritis. A contained lesion in an otherwise healthy joint points toward a scaffold approach. Widespread cartilage thinning across one or more compartments points toward a hydrogel cushioning strategy. The more nuanced middle group — patients who have a focal defect but also show early degenerative change elsewhere in the same joint — is where consultant judgement matters most. The evidence that pre-existing OA predicts poor ChondroFiller® outcomes means this group cannot simply receive the scaffold by default; whether a combination approach, a different sequencing, or an alternative pathway is appropriate depends on the individual's scan findings and symptom profile, and that determination cannot be made from the outside.

Where joint loading is part of the clinical picture — understanding which compartment bears the most mechanical stress, or whether a biomechanical factor may be accelerating the damage — objective movement analysis can add useful context alongside MRI. MAI Motion®, the MSK Doctors group's AI-powered markerless motion-capture system, quantifies loading patterns during everyday movement in a way that a static scan cannot, helping the team understand the forces acting on the affected area before any injection decision is finalised.

Appointments with a consultant — not a telephone triage — are available without referral or a GP letter. Book directly at mskdoctors.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12–60 month follow-up cohort. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] A Systematic Review of Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. (2022). https://doi.org/10.18103/mra.v10i8.2950 https://doi.org/10.18103/mra.v10i8.2950
4. [4] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24-month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Single intra-articular polyacrylamide hydrogel injection for knee OA: 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0
7. [7] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655